For the three months ending March 31, total revenue was 74,283.49 million CNY compared to 39.53% growth in the year-ago period with the total profit of 35, 813.66 million CNY compared to 76.23% growth over the same period last year. The net profit attributable to the shareholders of the listed company was 30, 847.85 million CNY, an increase of 83.46% over the same period last year. With the adjustment of the company' s instrument sales policy, the gross profit margin of main business increased by 1.02% year-on-year. In addition, with the gradual reduction of the impact of the share based payment fees of the restricted stock incentive plan in 2020, the company' s net interest rate increased by 9.94% year-on-year.

In the first quarter of 2022, the company completed the sales & installation of 1,648 automatic chemiluminescence instruments, of which 148 installed by MAGLUMI X8. By the end of the reporting period, the number of end customers in the domestic market had exceeded 7900 including 855 customers in the class III hospitals with 54.11% growth of the coverage rate of the class III hospitals. (According to the data of China Health Statistical Yearbook in 2021)

About Snibe (CACLP 2022 Booth No：A4-0413)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Briefed as Snibe Co.,Ltd.) is located in National Biological Industry Park(Shenzhen, China), founded in December 1995. Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. Snibe has formed a strong team of professionals: Reagents R & D and production center, Instruments R & D and production center, Sales & Marketing center.